Baird Financial Group Inc. grew its position in Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) by 12.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,192 shares of the biopharmaceutical company’s stock after purchasing an additional 879 shares during the period. Baird Financial Group Inc.’s holdings in Emergent BioSolutions were worth $254,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of EBS. Meeder Asset Management Inc. bought a new stake in Emergent BioSolutions during the first quarter worth about $46,000. Covestor Ltd increased its position in Emergent BioSolutions by 43.8% during the first quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 491 shares during the last quarter. Ancora Advisors LLC acquired a new position in Emergent BioSolutions during the first quarter worth approximately $66,000. Lazard Asset Management LLC acquired a new position in Emergent BioSolutions during the first quarter worth approximately $73,000. Finally, Islay Capital Management LLC acquired a new position in Emergent BioSolutions during the second quarter worth approximately $91,000. 81.54% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the company. Cowen lowered their price target on Emergent BioSolutions to $25.00 in a research report on Tuesday, November 15th. Cowen lowered their price target on Emergent BioSolutions from $30.00 to $29.00 and set a “market perform” rating on the stock in a research report on Monday, September 12th. Benchmark downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Thursday, November 10th. Chardan Capital decreased their target price on Emergent BioSolutions from $65.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, November 9th. Finally, StockNews.com downgraded Emergent BioSolutions from a “hold” rating to a “sell” rating in a research report on Monday, November 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $46.50.
Emergent BioSolutions Price Performance
About Emergent BioSolutions
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
- Get a free copy of the StockNews.com research report on Emergent BioSolutions (EBS)
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.